tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Karl Chalabala, 7 are a BUY (87.5%), 1 are a HOLD (12.5%).
Analyst Karl Chalabala, carries an average stock price target met ratio of 20.83% that have a potential upside of 5.72% achieved within 422 days. Previously, Karl Chalabala worked at UBS, STIFEL, CANACCORD.
Karl Chalabala’s has documented 19 price targets and ratings displayed on 6 stocks. The coverage was on Energy, Healthcare sectors.
Most recent stock forecast was given on FOLD, Amicus Therapeutics at 10-May-2024.
Analyst best performing recommendations are on EQT (EQT).
The best stock recommendation documented was for EQT (EQT) at 12/20/2012. The price target of $33.21 was fulfilled within 84 days with a profit of $3.85 (13.11%) receiving and performance score of 1.56.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Oct-2022
$73
$22.83 (45.51%)
$75
8 days ago
(29-Sep-2026)
12/22 (54.55%)
$24.12 (49.35%)
379
Buy Since 06-Dec-2024
$68
$17.83 (35.54%)
$67
14 days ago
(23-Sep-2026)
10/14 (71.43%)
$16.94 (33.18%)
281
Buy Since 15-Apr-2025
$71
$20.83 (41.52%)
$72
20 days ago
(17-Sep-2026)
6/12 (50%)
$20.65 (41.01%)
122
Buy Since 14-Jul-2025
$77
$26.83 (53.48%)
$73
23 days ago
(14-Sep-2026)
21/26 (80.77%)
$23.79 (44.71%)
185
Buy Since 20-Nov-2021
$67
$16.83 (33.55%)
$68
1 months 18 days ago
(19-Aug-2026)
25/29 (86.21%)
$13.36 (24.91%)
234
